Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Plasma deconvolution identifies broadly neutralizing antibodies associated with hepatitis C virus clearance
Valerie J. Kinchen, … , James E. Crowe Jr, Justin R. Bailey
Valerie J. Kinchen, … , James E. Crowe Jr, Justin R. Bailey
Published August 13, 2019
Citation Information: J Clin Invest. 2019;129(11):4786-4796. https://doi.org/10.1172/JCI130720.
View: Text | PDF
Research Article Immunology Virology

Plasma deconvolution identifies broadly neutralizing antibodies associated with hepatitis C virus clearance

  • Text
  • PDF
Abstract

A vaccine for hepatitis C virus (HCV) is urgently needed. Development of broadly neutralizing plasma antibodies during acute infection is associated with HCV clearance, but the viral epitopes of these plasma antibodies are unknown. Identifying these epitopes could define the specificity and function of neutralizing antibodies (NAbs) that should be induced by a vaccine. Here, we present the development and application of a high-throughput method that deconvolutes polyclonal anti-HCV NAbs in plasma, delineating the epitope specificities of anti-HCV NAbs in acute-infection plasma of 44 humans with subsequent clearance or persistence of HCV. Remarkably, we identified multiple broadly neutralizing antibody combinations that were associated with greater plasma neutralizing breadth and with HCV clearance. These studies have the potential to inform new strategies for vaccine development by identifying broadly neutralizing antibody combinations in plasma associated with the natural clearance of HCV, while also providing a high-throughput assay that could identify these responses after vaccination trials.

Authors

Valerie J. Kinchen, Guido Massaccesi, Andrew I. Flyak, Madeleine C. Mankowski, Michelle D. Colbert, William O. Osburn, Stuart C. Ray, Andrea L. Cox, James E. Crowe Jr, Justin R. Bailey

×

Figure 2

Selection of a reference mAb panel.

Options: View larger image (or click on image) Download as PowerPoint
Selection of a reference mAb panel.
(A) Main-chain atoms of previously d...
(A) Main-chain atoms of previously defined mAb binding residues identified by alanine-scanning mutagenesis (see Methods) marked with colored spheres on the crystallized structure of the HCV E2 protein ectodomain (gray), strain 1b09, PDB accession 6MEI (15), with colors modified in PyMOL, v1.8.6.2. For clarity, a maximum of 5 residues with impact on binding of each mAb are marked. Antigenic domains/antigenic regions (ARs) are indicated, and mAbs highlighted with the same color share multiple binding residues. Dashed lines indicate a disordered region (HVR1) or part of the E2 protein truncated to aid crystallization (stem region of E2). Putative AR4A and AR5A binding residues on E1 are not shown. (B) Neutralizing breadth of reference mAbs at 10 μg/mL measured with a panel of 19 genotype 1 HCVpp, with a threshold of 50% neutralization considered positive. (C) Functional grouping of reference mAbs. For each mAb, neutralization of each of 19 HCVpp was measured in duplicate, generating a neutralization profile (i.e., ranking of relative neutralization of each HCVpp) (Supplemental Figure 2), and pairwise Pearson correlations were measured between these neutralization profiles. Circles at each intersection of the heatmap are scaled by the magnitude of the correlation (r) between the indicated NAbs. mAbs were grouped into an NAb type if the neutralization profile of each mAb in the group had a correlation of greater than or equal to 0.55 with every other mAb in the group. One representative mAb (indicated with an asterisk) was selected from each NAb type to form the final panel of 8 reference mAbs.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts